Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T13:26:21.470Z.
Calculation as of: 2026-10-06T13:26:21.470Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5811ce025d9976e80ea69b9f8bae613fc78d61205a97c72640e2bc4d521a59ba
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Eloxx Pharmaceuticals, Inc.
Market Cap
$52.95M
EV/EBIT Ratio
N/A
| NAME | MARKET CAP | EV/EBIT RATIO |
|---|---|---|
| Eloxx Pharmaceuticals, Inc. (ELOX) | $52.95M | N/A |
| ImageneBio Inc (IMA)vs › | $53.01M | N/A |
| INmune Bio, Inc. (INMB)vs › | $51.58M | N/A |
| eXoZymes, Inc. (EXOZ)vs › | $51.23M | N/A |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $51.12M | N/A |
| Apollomics, Inc. (APLM)vs › | $51.17M | N/A |
| Envoy Medical, Inc. (COCH)vs › | $50.25M | N/A |
| Aldeyra The (ALDX)vs › | $57.31M | N/A |
| Clene Inc. (CLNN)vs › | $49.96M | N/A |
| Celularity Inc. (CELU)vs › | $49.50M | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
